Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis.

Sarah E ThomasLiana BarenbrugGerjon HanninkMarieke M B SeygerElke M G J de JongJuul M P A van den Reek

Published in: Drugs (2024)

This meta-analysis showed that the investigated IL-17 and IL-23 inhibitors had high drug survival rates, with highest rates for guselkumab and risankizumab drug survival. We showed that effect modifiers such as biologic naivety, and the source of data used (registry/electronic health record data vs pharmacy/claims databases) is relevant when interpreting drug survival studies.

Keyphrases

electronic health record
adverse drug
systematic review
free survival
big data
rheumatoid arthritis
drug induced
case control
machine learning
atomic force microscopy
single molecule